Trending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials
1250 GMT - Merck is among the most mentioned companies across news items over the past 12 hours, according to Factiva data, after the German pharmaceutical-and-chemical group said its multiple sclerosis drug didn't meet expectations in a late-stage trial. The drug didn't show strong enough efficacy in reducing annualized relapse rates and therefore missed the company's aim to match the results of Aubagio, a drug for the disease owned by the French drug giant Sanofi. The news is negative from a strategic point of view, as it reduces the pipeline value, Equita analyst Gianmarco Bonacina says in a research note. However, the analyst also points out that expectations for sales of this drug had been significantly reduced and were almost slashed to zero in April, after Merck flagged liver problems shown by two patients in the sample under examination. Sentiment towards the bruton tyrosine kinase inhibitors won't be helped by Merck's failure of evobrutinib to demonstrate superiority over Aubagio, given the class is already clouded by liver toxicity concerns, Citi analysts write in a note to clients. Now the main drug in the pipeline is xevinapant to treat cancer in the head and neck region, with readout of the Phase 3 trial in the next six months, Equita says. Dow Jones & Co. owns Factiva. (andrea.figueras@wsj.com)
(END) Dow Jones Newswires
December 06, 2023 08:05 ET (13:05 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
Arm Earnings: Shares Fall as 2025 Guidance Disappoints Investors